Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant in Pulmonary Arterial Hypertension
NCT02911844Phase 2Completed
- Sponsor
- University of Pennsylvania
- Start
- Apr 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fulvestrant in pulmonary arterial hypertension (PAH), sponsored by University of Pennsylvania. Primary endpoints: Plasma Estradiol Levels at 9 weeks, Tricuspid Annular Plane Systolic Excursion at 9 weeks and 2 more. Started Apr 2017; status: completed.
02
Drugs
fulvestrant
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02911844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02911844.